Drugs / VRC-FLUNPF0103-00-VP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04579250 | Oct 2020 → Jan 2022 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-FLUNPF0103-00-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04579250 ↗ |
| Known as | H10ssF-6473 | “The investigational vaccine, VRC-FLUNPF0103-00-VP (H10ssF-6473), was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases...” NCT04579250 ↗ |
| Modality | Vaccine | “The investigational vaccine” NCT04579250 ↗ |
| Route | Intramuscular | “Prepared study product was administered intramuscularly (IM) in the deltoid muscle via needle and syringe.” NCT04579250 ↗ |